Below are the most recent publications written about "Viral Vaccines" by people in Profiles.
-
Escalante GM, Reidel IG, Mutsvunguma LZ, Cua S, Tello BA, Rodriguez E, Farelo MA, Zimmerman C, Muniraju M, Li H, Govindan AN, Axthelm MK, Wong SW, Ogembo JG. Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice. Front Immunol. 2024; 15:1445209.
-
Olearo F, Radmanesh LS, Felber N, von Possel R, Emmerich P, Pekarek N, Pfefferle S, N?rz D, Hansen G, Diemert A, Aepfelbacher M, Hecher K, L?tgehetmann M, Arck PC, Tallarek AC. Anti-SARS-CoV-2 antibodies in breast milk during lactation after infection or vaccination: A cohort study. J Reprod Immunol. 2022 09; 153:103685.
-
Bagno FF, Andrade LAF, S?rgio SAR, Parise PL, Toledo-Teixeira DA, Gazzinelli RT, Fernandes APSM, Teixeira SMR, Granja F, Proen?a-M?dena JL, da Fonseca FG. Previous Infection with SARS-CoV-2 Correlates with Increased Protective Humoral Responses after a Single Dose of an Inactivated COVID-19 Vaccine. Viruses. 2022 03 02; 14(3).
-
He X, Chandrashekar A, Zahn R, Wegmann F, Yu J, Mercado NB, McMahan K, Martinot AJ, Piedra-Mora C, Beecy S, Ducat S, Chamanza R, Huber SR, van Heerden M, van der Fits L, Borducchi EN, Lifton M, Liu J, Nampanya F, Patel S, Peter L, Tostanoski LH, Pessaint L, Van Ry A, Finneyfrock B, Velasco J, Teow E, Brown R, Cook A, Andersen H, Lewis MG, Schuitemaker H, Barouch DH. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell. 2021 06 24; 184(13):3467-3473.e11.
-
Kurt-Jones EA, Dudek TE, Watanabe D, Mandell L, Che J, Zhou S, Cao L, Greenough T, Babcock GJ, Diaz F, Oh HS, Zhou C, Finberg RW, Knipe DM. Expression of SARS coronavirus 1 spike protein from a herpesviral vector induces innate immune signaling and neutralizing antibody responses. Virology. 2021 07; 559:165-172.
-
Bartsch YC, Fischinger S, Siddiqui SM, Chen Z, Yu J, Gebre M, Atyeo C, Gorman MJ, Zhu AL, Kang J, Burke JS, Slein M, Gluck MJ, Beger S, Hu Y, Rhee J, Petersen E, Mormann B, Aubin MS, Hasdianda MA, Jambaulikar G, Boyer EW, Sabeti PC, Barouch DH, Julg BD, Musk ER, Menon AS, Lauffenburger DA, Nilles EJ, Alter G. Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nat Commun. 2021 02 15; 12(1):1018.
-
Osier F, Ting JPY, Fraser J, Lambrecht BN, Romano M, Gazzinelli RT, Bortoluci KR, Zamboni DS, Akbar AN, Evans J, Brown DE, Patel KD, Wu Y, Perez AB, P?rez O, Kamradt T, Falk C, Barda-Saad M, Ariel A, Santoni A, Annunziato F, Cassatella MA, Kiyono H, Chereshnev V, Dieye A, Mbow M, Mbengue B, Niang MDS, Suchard M. The global response to the COVID-19 pandemic: how have immunology societies contributed? Nat Rev Immunol. 2020 10; 20(10):594-602.
-
Colby DJ, Sarnecki M, Barouch DH, Tipsuk S, Stieh DJ, Kroon E, Schuetz A, Intasan J, Sacdalan C, Pinyakorn S, Grandin P, Song H, Tovanabutra S, Shubin Z, Kim D, Paquin-Proulx D, Eller MA, Thomas R, de Souza M, Wieczorek L, Polonis VR, Pagliuzza A, Chomont N, Peter L, Nkolola JP, Vingerhoets J, Truyers C, Pau MG, Schuitemaker H, Phanuphak N, Michael N, Robb ML, Tomaka FL, Ananworanich J. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat Med. 2020 04; 26(4):498-501.
-
Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect. 2020; 9(1):542-544.
-
McGinnes Cullen L, Schmidt MR, Morrison TG. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles. J Virol. 2019 05 01; 93(9).